Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01502410 · OUTCOME

The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity,

Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer · Source last updated 2018-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
six cycles of chemotherapy; expected to be 126 days of treatment

What was measured

Each patient is classified as having experienced grade 3 or higher CTC version 4 toxicity if at any time during protocol therapy such an event is observed for the individual.

Analysis population: All eligible patients diagnosed with Rhabdomyosarcoma or Wilms Tumor are combined in this analysis.

Groups in this outcome

Rhabdomyosarcoma and Wilms Tumor

These are the responses of the patient's organs to the drug. As such, these measures are unrelated to the particular diagnosed disease. Therefore, both Rhabdomyosarcoma and Wilms Tumor are combined in this analysis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rhabdomyosarcoma and Wilms Tumor20

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Rhabdomyosarcoma and Wilms Tumor14Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        14
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Each patient is classified as having experienced grade 3 or higher CTC version 4 toxicity if at any time during protocol therapy such an event is observed for the individual.
groups
  1. description
    These are the responses of the patient's organs to the drug. As such, these measures are unrelated to the particular diagnosed disease. Therefore, both Rhabdomyosarcoma and Wilms Tumor are combined in this analysis.
    id
    OG000
    title
    Rhabdomyosarcoma and Wilms Tumor
param Type
COUNT_OF_PARTICIPANTS
population Description
All eligible patients diagnosed with Rhabdomyosarcoma or Wilms Tumor are combined in this analysis.
reporting Status
POSTED
time Frame
six cycles of chemotherapy; expected to be 126 days of treatment
title
The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity,
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice